Co-Diagnostics Inc
NASDAQ:CODX
Co-Diagnostics Inc
Accounts Payable
Co-Diagnostics Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Co-Diagnostics Inc
NASDAQ:CODX
|
Accounts Payable
$1.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Accounts Payable
$1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
17%
|
|
|
Stryker Corp
NYSE:SYK
|
Accounts Payable
$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
16%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Accounts Payable
$4.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
14%
|
|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Accounts Payable
$122.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Accounts Payable
$255.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
26%
|
CAGR 10-Years
17%
|
|
Co-Diagnostics Inc
Glance View
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
See Also
What is Co-Diagnostics Inc's Accounts Payable?
Accounts Payable
1.5m
USD
Based on the financial report for Sep 30, 2025, Co-Diagnostics Inc's Accounts Payable amounts to 1.5m USD.
What is Co-Diagnostics Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
37%
Over the last year, the Accounts Payable growth was -33%. The average annual Accounts Payable growth rates for Co-Diagnostics Inc have been -11% over the past three years , 37% over the past five years .
